Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy

AIDS

Volumn 16, Issue 8, 2002, Pages 1139-1146

  Frater, Alexander J ^a   Dunn, David T ^b   Beardall, Alison J ^a   Ariyoshi, Koya ^c   Clarke, John R ^a   McClure, Myra O ^a   Weber, Jonathan N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Africa; Antiretroviral therapy; HIV drug resistance; HIV subtypes; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; POL PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEGRO; PHYLOGENY; PRIORITY JOURNAL; RACE; SEQUENCE ANALYSIS; SURVIVAL TIME; T LYMPHOCYTE; UNITED KINGDOM; VIRUS LOAD;

ADULT; AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPE; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037165924     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205240-00007     Document Type: Article

References (31)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
4. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
5. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population
6. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
7. HIV-1 nomenclature proposal
8. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort
9. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes
10. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy
11. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses
12. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
13. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
14. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates
15. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nudeoside resistance
16. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART
17. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe
18. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomised Trial
19. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
20. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 Study)
21. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials
22. Robust confidence intervals using maximum likelihood estimators
23. Equivalence in virological responses to HAART in patients with HIV-1 subtype non-B infections: A case-controlled study (n = 100)
24. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients
25. Resistance to antiretroviral therapy among patients in Uganda
26. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire
27. The impact of HIV-1 subtype on drug-resistant HIV-1 strains
28. Disease progression and survival in HIV-1-infected Africans in London
29. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
30. Adherence to antiretrovirals in HIV disease